Por lo Qué Hasta la Obtención de los Resultados Completos ... Más la Elaboración del Dossier ... Más la Evaluación de las Agencias ... Nos Podemos Ir al 2027 .
21 junio 2007
NeuroPharma Patente : Dibenzene derivatives as calcium channel blockers .
Dibenzene derivatives as calcium channel blockers
Publication number: EP1798220 Publication date: 2007-06-20 Inventor: MARTINEZ GIL ANA (ES); CASTRO MORERA ANA (ES); MEDINA PADILLA MIGUEL (ES); MUNOZ RUIZ PILAR (ES); RUBIO ARRIETA LAURA (ES); GARCIA PALOMERO ESTHER (ES); DE AUSTRIA CELIA (ES) Applicant: NEUROPHARMA S A (ES) Classification: - international: C07C255/60; A61K31/166; A61P25/28; C07C255/00; A61K31/166; A61P25/00; - European: Application number: EP20050077910 20051216 Priority number(s): EP20050077910 20051216
Abstract of EP1798220 The invention is directed to a compound of formula (I) Having VDCC blocking activity. These compounds are useful for the treatment of a series of human diseases and conditions, especially cognitive or neurodegenerative diseases or conditions.
Publication number: EP1798220 Publication date: 2007-06-20 Inventor: MARTINEZ GIL ANA (ES); CASTRO MORERA ANA (ES); MEDINA PADILLA MIGUEL (ES); MUNOZ RUIZ PILAR (ES); RUBIO ARRIETA LAURA (ES); GARCIA PALOMERO ESTHER (ES); DE AUSTRIA CELIA (ES) Applicant: NEUROPHARMA S A (ES) Classification: - international: C07C255/60; A61K31/166; A61P25/28; C07C255/00; A61K31/166; A61P25/00; - European: Application number: EP20050077910 20051216 Priority number(s): EP20050077910 20051216
Abstract of EP1798220 The invention is directed to a compound of formula (I) Having VDCC blocking activity. These compounds are useful for the treatment of a series of human diseases and conditions, especially cognitive or neurodegenerative diseases or conditions.
ANTITUMORAL ANALOGS OF ET-743, PHARMACEUTICAL COMPOSITION BASED THEREON AND USE THEREOF .
ANTITUMORAL ANALOGS OF ET-743, PHARMACEUTICAL COMPOSITION BASED THEREON AND USE THEREOF .
Publication number: UA78680 Publication date: 2007-04-25 Inventor: MARTIN MARIA JESUS (ES) Applicant: PHARMA MAR SA (ES) Classification: - international: A61K31/499; A61P31/04; A61P35/00; C07D471/18; C07D471/22; C07D487/18; C07D491/22; C07D515/00; A61K31/499; A61P31/00; A61P35/00; C07D471/00; C07D487/00; C07D491/00; C07D515/00; - European: Application number: UA20021210092 20010515 Priority number(s): WO2000GB01852 20000515; WO2001GB02110 20010515
Abstract of UA78680 Antitumour compounds have the five membered fused ring ecleinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group. , (XIV)
Publication number: UA78680 Publication date: 2007-04-25 Inventor: MARTIN MARIA JESUS (ES) Applicant: PHARMA MAR SA (ES) Classification: - international: A61K31/499; A61P31/04; A61P35/00; C07D471/18; C07D471/22; C07D487/18; C07D491/22; C07D515/00; A61K31/499; A61P31/00; A61P35/00; C07D471/00; C07D487/00; C07D491/00; C07D515/00; - European: Application number: UA20021210092 20010515 Priority number(s): WO2000GB01852 20000515; WO2001GB02110 20010515
Abstract of UA78680 Antitumour compounds have the five membered fused ring ecleinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group. , (XIV)
Suscribirse a:
Entradas (Atom)